In individuals affected by PCA, there is a significant downregulation of genes associated with the cholesterol biosynthetic pathway. by Leemon Nikhila (22250736)

Demonstration of decreased Aβ accumulation by DA-9601 treatment. by Mijung Lee (397790)

Volitional control frequency and intensity in VH (Kapsner-Smith et al., 2025) by Mara R. Kapsner-Smith (22139315)

“…Group differences were tested with general linear models.</p><p dir="ltr"><b>Results: </b>No significant differences were found between people with and without HVDs on any of the measures. …”

Juvenile demyelination leads to a substantial decrease in potassium currents in PV interneurons of the PFC. by Sara Hijazi (21656615)

“…Scale: 500 pA, 100 ms. <b>B</b>. I–V curves showing a significant decrease in Kv amplitude in PV interneurons from mice that underwent juvenile demyelination. …”

Decrease of cellular cAMP levels in response to a concentration range of melatonin treatments. by Cathryn S. D. Maienza (20629929)

Linear regression equation and concentration range of each SCFAs standard. by Shudan Liu (7049483)

Lymphocytes decreased in mouse pneumonia model. by Qi Xu (134661)

CKO mice display decreased skin barrier function and perturbed homeostasis. by Kevin J. Mills (9270966)

GLS inhibition decreases IL-1β secretion <i>in vitro</i>. by Bárbara Ponzilacqua-Silva (17002156)

Linear trends of the weekly total cost and cost components per capita for inpatients in the surgical group. by Chenxuan Zhu (22622476)

Image 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Image 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Image 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Table 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.docx by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Table 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Table 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Image 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Table 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Scatterplot of observed barrier scores against knowledge scores (top) and confidence scores (bottom) with linear line of best fit. by Lisa Thiele (6468056)

A) RT-qPCR analysis of <i>Yap</i>, <i>Taz</i>, and <i>Tead2</i> shows a significant decrease in transcript levels over postnatal stages from P0 to P28. by Heather L. Dingwall (14573796)